ANADYS PHARMA (NASDAQ:ANDS)
2.19
+0.03 (1.39%)
| ANADYS PHARMA (NASDAQ:ANDS) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $2.16 | 52 Week High | $8.43 | ||
| Open | $2.13 | 52 Week Low | $1.44 | ||
| Day High | $2.19 | P/E | N/A | ||
| Day Low | $2.10 | EPS | $-1.02 | ||
| Volume | 248,321 | ||||
| More ANDS Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| LVS | 4 | NVTL | 3 |
| ARIA | 3 | PKI | 3 |
| GPRO | 3 | SYNA | 3 |
| PETD | 2 | VPRT | 2 |
| DSCM | 2 | OFIX | 2 |
| MHK | 2 | VSEA | 2 |
Entities who have mentioned ANDS
- Piper Jaffray | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- ThinkEquity | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Morgan Stanley | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Jefferies & Co | View Related Stories »
- JMP Securities | View Related Stories »
- Bakken Formation | View Related Stories »
- Needham & Co | View Related Stories »
- Deutsche Bank | View Related Stories »
- Morningstar, Inc. | View Related Stories »
- Trading Radar | View Related Stories »
- After-Hours Movers | View Related Stories »
- Piper Jaffray Alpha List | View Related Stories »
- JPMorgan | View Related Stories »
- Wedbush Morgan | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- Lazard | View Related Stories »
- Collins Stewart | View Related Stories »
- Stock Buyback | View Related Stories »
- RBC Capital | View Related Stories »
- Bankruptcy | View Related Stories »
- Cowen & Co | View Related Stories »
- UBS | View Related Stories »
View All Major News StreetInsider.com Major News for ANDS
- Anadys Pharmaceuticals (ANDS) Reports Smaller Q2 Loss
- Anadys Pharmaceuticals (ANDS) Tops Q1 EPS by 1c
- Anadys Pharmaceuticals (ANDS) Tops Q4 EPS by 3c; No Revenues Reported
View All ReportsStreetInsider.com Reports on ANDS
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- National Securities Initiates Coverage on Anadys Pharmaceuticals (ANDS) with a Buy
- Wedbush Assumes and Initiates Coverage on Several Key Biotech Players in Anti-Viral Space
- Morning Movers 8/11: AVNR, RWC, HLCS, ANPI, ANDS, AGM Higher; JAV, BIDZ, PETD, AHR, CIT, FTK, CLNE Lower
View All Press ReleasesCompany Press Releases on ANDS
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
- Anadys Pharmaceuticals to Report Third Quarter 2009 Financial Results
- Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
- Anadys Pharmaceuticals to present at the JMP Securities Healthcare Focus Conference
StreetInsider Reports on ANDS by Category
View All BlogsBlogs on ANDS
- Anadys: Better Speculative Plays Out There
- Closing Update for Tuesday, August 11: Back-to-Back Losses
- Extreme FDA Trades: 30 Stocks Under 5 Bucks
- Closing Update for Friday, July 31
- FDA Calendar Updates: Anadys, Merck, Schering-Plough
View All FilingsSEC Filings on ANDS
- Form 10-Q ANADYS PHARMACEUTICALS For: Sep 30
- Form 8-K ANADYS PHARMACEUTICALS For: Oct 29
- Form 4 Holtzman Steven H For: Oct 06
Comments on ANDS
No comments are currently available.
